Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Impact of Comorbidity on Treatment Response to Paroxetine in Pediatric Obsessive-Compulsive Disorder: Is the Use of Exclusion Criteria Empirically Supported in Randomized Clinical Trials?

Geller, Daniel A., Biederman, Joseph, Stewart, S. Evelyn, Mullin, Benjamin, Farrell, Colleen, Wagner, Karen Dineen, Emslie, Graham, Carpenter, David·2003·Journal of Child and Adolescent Psychopharmacology

Abstract

OBJECTIVE: To examine the influence of psychiatric comorbidity on response and relapse rates in children and adolescents treated with paroxetine for obsessive-compulsive disorder (OCD). METHODS: Patients responding following 16 weeks of treatment (phase I) were randomized to continued paroxetine or to placebo for 16 additional weeks (phase II). OCD response (phase I) and relapse (phase II) criteria were based on the Clinical Global Impression-Improvement Scale and the Children's Yale-Brown Obsessive Compulsive Scale. The presence of OCD and other psychiatric disorders was ascertained using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version interview. RESULTS: At entry, 193 of 335 (57.6%) patients had at least one psychiatric disorder in addition to OCD, and 102 of 335 (30.4%) had multiple other disorders. Although the response rate to paroxetine in the overall population was high (71%), the response rates in patients with comorbid attention deficit hyperactivity disorder, tic disorder, or oppositional defiant disorder (56%, 53%, and 39%, respectively) were significantly less than in patients with OCD only (75%) (intent-to-treat population, last observation carried forward analysis, p < 0.05). Psychiatric comorbidity was associated with a greater rate of relapse in the total patient population (46% for one or more comorbid disorders [p = 0.04] and 56% for two or more comorbid disorders [p < 0.05] vs. 32% for no comorbidity). CONCLUSIONS: The results of these post hoc analyses show that comorbid illness adversely impacted response to pharmacotherapy with paroxetine in pediatric OCD and significantly increased risk of relapse following withdrawal from treatment. Continued paroxetine treatment reduced the relapse rates in all groups compared with placebo, including those with comorbid illness. Because pediatric OCD is frequently comorbid with other psychiatric disorders, results of randomized, controlled pediatric OCD trials that use multiple exclusion criteria may not generalize to more naturalistic OCD samples.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/104454603322126313

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 187

Metadata

Authors
Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Farrell, C., Wagner, K. D., Emslie, G., & Carpenter, D.
Venue
Journal of Child and Adolescent Psychopharmacology
Published
2003-07
Volume
13
Issue
supplement 1
Pages
19-29
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
OpenAlex
W2031675036
Cited by
187
References
6
FWCI
8.69
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Comorbidity on Treatment Response to Paroxetine in Pediatric Obsessive-Compulsive Disorder: Is the Use of Exclusion Criteria Empirically Supported in Randomized Clinical Trials? https://app.cochat.ai/papers/10.1089/104454603322126313
The paper
Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Farrell, C., Wagner, K. D., Emslie, G., & Carpenter, D. (2003). Impact of Comorbidity on Treatment Response to Paroxetine in Pediatric Obsessive-Compulsive Disorder: Is the Use of Exclusion Criteria Empirically Supported in Randomized Clinical Trials? Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/104454603322126313

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.